BIGBEAR
PHARMACEUTICALS
Cobimetinib first received marketing authorization in the European Union in 2015. It is a highly selective, reversible allosteric inhibitor of mitogen-activated protein kinase (MEK) 1/2.
AuthenticGuaranteeFast DeliveryPrivacy Cobimetinib is a targeted therapeutic agent belonging to the MEK inhibitor class. It inhibits tumor cell growth by blocking the activity of key protei···【Read More】
Update: 27 Feb,2026Source: Haiou HealthViews: 71
Copyright2024@ BIGBEAR All right reserved BIGBEAR
